It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ALVO’s FA Score shows that 1 FA rating(s) are green while.
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ALVO’s TA Score shows that 5 TA indicator(s) are bullish.
ALVO (@Pharmaceuticals: Other) experienced а +18.14% price change this weekfor the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was -1.21%. For the same industry, the average monthly price growth was +11.99%, and the average quarterly price growth was +4.71%.
ALVO is expected to report earnings on Aug 13, 2025.
Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
ALVO | |
Capitalization | 3.48B |
EBITDA | -493.67M |
Gain YTD | -29.101 |
P/E Ratio | 57.47 |
Revenue | 91.4M |
Total Cash | 11.2M |
Total Debt | 1.08B |
ALVO | |
---|---|
RSI ODDS (%) | 1 day ago75% |
Stochastic ODDS (%) | 1 day ago50% |
Momentum ODDS (%) | 1 day ago45% |
MACD ODDS (%) | 1 day ago42% |
TrendWeek ODDS (%) | 1 day ago54% |
TrendMonth ODDS (%) | 1 day ago52% |
Advances ODDS (%) | 4 days ago62% |
Declines ODDS (%) | 2 days ago66% |
BollingerBands ODDS (%) | 1 day ago53% |
Aroon ODDS (%) | 1 day ago63% |
A.I.dvisor tells us that ALVO and EBS have been poorly correlated (+26% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that ALVO and EBS's prices will move in lockstep.
Ticker / NAME | Correlation To ALVO | 1D Price Change % | ||
---|---|---|---|---|
ALVO | 100% | +18.14% | ||
EBS - ALVO | 26% Poorly correlated | +34.18% | ||
PBH - ALVO | 25% Poorly correlated | +6.92% | ||
AKAN - ALVO | 24% Poorly correlated | +4.29% | ||
RDY - ALVO | 23% Poorly correlated | -2.51% | ||
KMDA - ALVO | 23% Poorly correlated | +2.64% | ||
More |